Back to Search
Start Over
Prise en charge du cancer du col de l’utérus métastatique et/ou en rechute.
- Source :
-
Bulletin du cancer [Bull Cancer] 2017 May; Vol. 104 Suppl 1, pp. S39-S42. - Publication Year :
- 2017
-
Abstract
- Metastatic or Recurrent Cervical Cancer/treatment: The prognosis of metastatic or recurrent cervical cancer remains dismal. The poor chemosensitivity of this tumor- is an issue, especially in case of recurrence in irradiated fields. Still, chemotherapy has shown some efficacy, and mostly consists in platinum-based doublets. The addition of bevacizumab to chemotherapy has been recently validated. However, most of these patients present with complex clinical situations and the treatment strategy has to be discussed in multidisciplinary tumor boards.<br /> (© 2017 Elsevier Masson SAS. Tous droits réservés.)
- Subjects :
- Bevacizumab therapeutic use
Female
Humans
Neoplasm Metastasis
Angiogenesis Inhibitors therapeutic use
Antineoplastic Agents therapeutic use
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Neoplasm Recurrence, Local drug therapy
Uterine Cervical Neoplasms drug therapy
Uterine Cervical Neoplasms pathology
Subjects
Details
- Language :
- French
- ISSN :
- 1769-6917
- Volume :
- 104 Suppl 1
- Database :
- MEDLINE
- Journal :
- Bulletin du cancer
- Publication Type :
- Academic Journal
- Accession number :
- 28625314
- Full Text :
- https://doi.org/10.1016/S0007-4551(17)30161-3